Novel Mechanisms of Sildenafil in Pulmonary Hypertension Involving Cytokines/chemokines, MAP Kinases and Akt

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2014 Aug 19

PMID 25133539

Citations 20

Authors

Tamas Kiss

Andras Komocsi

Adrienn Tornyos

Petra Zalan

Balazs Sumegi

Ferenc Gallyas Jr

Krisztina Kovacs

Affiliations

Soon will be listed here.

Abstract

Pulmonary arterial hypertension (PH) is associated with high mortality due to right ventricular failure and hypoxia, therefore to understand the mechanism by which pulmonary vascular remodeling initiates these processes is very important. We used a well-characterized monocrotaline (MCT)-induced rat PH model, and analyzed lung morphology, expression of cytokines, mitogen-activated protein kinase (MAPK) phosphorylation, and phosphatidylinositol 3-kinase-Akt (PI-3k-Akt) pathway and nuclear factor (NF)-κB activation in order to elucidate the mechanisms by which sildenafil's protective effect in PH is exerted. Besides its protective effect on lung morphology, sildenafil suppressed multiple cytokines involved in neutrophil and mononuclear cells recruitment including cytokine-induced neutrophil chemoattractant (CINC)-1, CINC-2α/β, tissue inhibitor of metalloproteinase (TIMP)-1, interleukin (IL)-1α, lipopolysaccharide induced CXC chemokine (LIX), monokine induced by gamma interferon (MIG), macrophage inflammatory protein (MIP)-1α, and MIP-3α. NF-κB activation and phosphorylation were also attenuated by sildenafil. Furthermore, sildenafil reduced extracellular signal-regulated kinase (ERK)1/2 and p38 MAPK activation while enhanced activation of the cytoprotective Akt pathway in PH. These data suggest a beneficial effect of sildenafil on inflammatory and kinase signaling mechanisms that substantially contribute to its protective effects, and may have potential implications in designing future therapeutic strategies in the treatment of pulmonary hypertension.

Citing Articles

Exploring the Multifaceted Potential of Sildenafil in Medicine.

Puscasu C, Zanfirescu A, Negres S, Seremet O Medicina (Kaunas). 2023; 59(12).

PMID: 38138293 PMC: 10744870. DOI: 10.3390/medicina59122190.

Pathophysiology and pathogenic mechanisms of pulmonary hypertension: role of membrane receptors, ion channels, and Ca signaling.

Balistrieri A, Makino A, Yuan J Physiol Rev. 2022; 103(3):1827-1897.

PMID: 36422993 PMC: 10110735. DOI: 10.1152/physrev.00030.2021.

Reversal of pulmonary arterial hypertension and neointimal formation by kinin B1 receptor blockade.

Rampa D, Murugesan P, Chao H, Feng H, Dai W, Lee D Respir Res. 2021; 22(1):281.

PMID: 34717626 PMC: 8557528. DOI: 10.1186/s12931-021-01875-w.

Sildenafil in endotoxin-induced pulmonary hypertension: an experimental study.

Kemper D, Otsuki D, Maia D, Mossoco C, Marcasso R, Cunha L Braz J Anesthesiol. 2021; 73(4):446-454.

PMID: 34118261 PMC: 10362450. DOI: 10.1016/j.bjane.2021.05.016.

COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors.

Al-Kuraishy H, Al-Gareeb A, Al-Niemi M, Al-Buhadily A, Al-Harchan N, Lugnier C J Microsc Ultrastruct. 2021; 8(4):141-145.

PMID: 33623736 PMC: 7883493. DOI: 10.4103/JMAU.JMAU_63_20.

References

Lagente V, Naline E, Guenon I, Corbel M, Boichot E, Burgaud J . A nitric oxide-releasing salbutamol elicits potent relaxant and anti-inflammatory activities. J Pharmacol Exp Ther. 2004; 310(1):367-75. DOI: 10.1124/jpet.103.061739. View

Wilson D, Segall H, Pan L, Dunston S . Progressive inflammatory and structural changes in the pulmonary vasculature of monocrotaline-treated rats. Microvasc Res. 1989; 38(1):57-80. DOI: 10.1016/0026-2862(89)90017-4. View

ALEXANDRU B, Bogdan M . [Monocrotaline induce pulmonary hypertension in animal models]. Pneumologia. 2001; 50(2):85-9. View

Moreno-Vinasco L, Gomberg-Maitland M, Maitland M, Desai A, Singleton P, Sammani S . Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics. 2008; 33(2):278-91. PMC: 3616402. DOI: 10.1152/physiolgenomics.00169.2007. View

Chan S, Loscalzo J . Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol. 2007; 44(1):14-30. PMC: 2234575. DOI: 10.1016/j.yjmcc.2007.09.006. View

Lu J, Shimpo H, Shimamoto A, Chong A, Hampton C, Spring D . Specific inhibition of p38 mitogen-activated protein kinase with FR167653 attenuates vascular proliferation in monocrotaline-induced pulmonary hypertension in rats. J Thorac Cardiovasc Surg. 2004; 128(6):850-9. DOI: 10.1016/j.jtcvs.2004.03.003. View

Wang T, Liu Y, Chen L, Wang X, Hu X, Feng Y . Effect of sildenafil on acrolein-induced airway inflammation and mucus production in rats. Eur Respir J. 2009; 33(5):1122-32. DOI: 10.1183/09031936.00055908. View

Guo Y, Huang H, Zeng D, Zhao J, Fang H, Lavoie J . Interleukin (IL)-4 induces production of cytokine-induced neutrophil chemoattractants (CINCs) and intercellular adhesion molecule (ICAM)-1 in lungs of asthmatic rats. J Huazhong Univ Sci Technolog Med Sci. 2013; 33(4):470-478. DOI: 10.1007/s11596-013-1144-5. View

Suwara M, Green N, Borthwick L, Mann J, Mayer-Barber K, Barron L . IL-1α released from damaged epithelial cells is sufficient and essential to trigger inflammatory responses in human lung fibroblasts. Mucosal Immunol. 2013; 7(3):684-93. PMC: 3931585. DOI: 10.1038/mi.2013.87. View

10.

Clayton R, Dick C, Mackenzie A, Nagasawa M, Galbraith D, Hastings S . The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma. Respir Res. 2004; 5:4. PMC: 419478. DOI: 10.1186/1465-9921-5-4. View

11.

Thanos D, Maniatis T . NF-kappa B: a lesson in family values. Cell. 1995; 80(4):529-32. DOI: 10.1016/0092-8674(95)90506-5. View

12.

Perkins N . Integrating cell-signalling pathways with NF-kappaB and IKK function. Nat Rev Mol Cell Biol. 2006; 8(1):49-62. DOI: 10.1038/nrm2083. View

13.

Rubin L, Badesch D, Fleming T, Galie N, Simonneau G, Ghofrani H . Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. Chest. 2011; 140(5):1274-1283. DOI: 10.1378/chest.10-0969. View

14.

Nedvig K, Weber G, Nemeth J, Kovacs K, Reglodi D, Kemeny A . Changes of PACAP immunoreactivities and cytokine levels after PACAP-38 containing intestinal preservation and autotransplantation. J Mol Neurosci. 2012; 48(3):788-94. DOI: 10.1007/s12031-012-9870-x. View

15.

Schermuly R, Kreisselmeier K, Ghofrani H, Yilmaz H, Butrous G, Ermert L . Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med. 2003; 169(1):39-45. DOI: 10.1164/rccm.200302-282OC. View

16.

Marathe N, Rangaswami H, Zhuang S, Boss G, Pilz R . Pro-survival effects of 17β-estradiol on osteocytes are mediated by nitric oxide/cGMP via differential actions of cGMP-dependent protein kinases I and II. J Biol Chem. 2011; 287(2):978-88. PMC: 3256896. DOI: 10.1074/jbc.M111.294959. View

17.

Ross D, Strieter R, Fishbein M, Ardehali A, Belperio J . Type I immune response cytokine-chemokine cascade is associated with pulmonary arterial hypertension. J Heart Lung Transplant. 2012; 31(8):865-73. DOI: 10.1016/j.healun.2012.04.008. View

18.

Zeng Z, Li Y, Jiang Z, Wang C, Li B, Jiang W . The extracellular signal-regulated kinase is involved in the effects of sildenafil on pulmonary vascular remodeling. Cardiovasc Ther. 2010; 28(1):23-9. DOI: 10.1111/j.1755-5922.2009.00115.x. View

19.

Baeuerle P, Henkel T . Function and activation of NF-kappa B in the immune system. Annu Rev Immunol. 1994; 12:141-79. DOI: 10.1146/annurev.iy.12.040194.001041. View

20.

Wang Q, Zuo X, Wang Y, Xie W, Wang H, Zhang M . Monocrotaline-induced pulmonary arterial hypertension is attenuated by TNF-α antagonists via the suppression of TNF-α expression and NF-κB pathway in rats. Vascul Pharmacol. 2012; 58(1-2):71-7. DOI: 10.1016/j.vph.2012.07.006. View